Cargando…
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983075/ https://www.ncbi.nlm.nih.gov/pubmed/24741337 http://dx.doi.org/10.2147/PROM.S41768 |
_version_ | 1782311255329996800 |
---|---|
author | Planas, Raquel Martin, Roland Sospedra, Mireia |
author_facet | Planas, Raquel Martin, Roland Sospedra, Mireia |
author_sort | Planas, Raquel |
collection | PubMed |
description | Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-term studies confirm the considerable and sustained efficacy of natalizumab, although the PML complication still threatens one of the most successful treatments available for RRMS. During these years, considerable progress has been made in identification of risk factors that allow more effective management of PML risk. In addition, long-term studies to define better when to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are ongoing, and hopefully will improve management and will allow natalizumab to remain as a valuable therapeutic option for patients with highly active RRMS. |
format | Online Article Text |
id | pubmed-3983075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39830752014-04-16 Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life Planas, Raquel Martin, Roland Sospedra, Mireia Patient Relat Outcome Meas Review Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-term studies confirm the considerable and sustained efficacy of natalizumab, although the PML complication still threatens one of the most successful treatments available for RRMS. During these years, considerable progress has been made in identification of risk factors that allow more effective management of PML risk. In addition, long-term studies to define better when to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are ongoing, and hopefully will improve management and will allow natalizumab to remain as a valuable therapeutic option for patients with highly active RRMS. Dove Medical Press 2014-04-04 /pmc/articles/PMC3983075/ /pubmed/24741337 http://dx.doi.org/10.2147/PROM.S41768 Text en © 2014 Planas et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Planas, Raquel Martin, Roland Sospedra, Mireia Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title_full | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title_fullStr | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title_full_unstemmed | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title_short | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
title_sort | long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983075/ https://www.ncbi.nlm.nih.gov/pubmed/24741337 http://dx.doi.org/10.2147/PROM.S41768 |
work_keys_str_mv | AT planasraquel longtermsafetyandefficacyofnatalizumabinrelapsingremittingmultiplesclerosisimpactonqualityoflife AT martinroland longtermsafetyandefficacyofnatalizumabinrelapsingremittingmultiplesclerosisimpactonqualityoflife AT sospedramireia longtermsafetyandefficacyofnatalizumabinrelapsingremittingmultiplesclerosisimpactonqualityoflife |